Eli Lilly Breaks Above Key Resistance as Uptrend StrengthensEli Lilly and CompanyBATS:LLYfinvestnomicsLLY is attracting renewed buying interest following a healthy pullback, with the stock successfully reclaiming and closing above the key $1,114 resistance level for the second time. The shares remain in a strong uptrend, characterized by higher highs and higher lows, while continuing to trade above both the 20-day and 50-day moving averages. Eli Lilly and Company is a $1.06 trillion pharmaceutical leader focused on the discovery, development, manufacturing, and commercialization of therapies across diabetes, oncology, immunology, neuroscience, and other therapeutic areas. The company possesses a wide economic moat supported by its strong portfolio of innovative medicines, robust research capabilities, and significant scale advantages. Financial performance remains impressive, with revenue and earnings per share growing over the last three quarters. Profitability metrics are exceptional, with operating and net margins of 49% and 37%, respectively. The company also generates outstanding returns on capital, evidenced by a return on equity (ROE) of 108% and a return on invested capital (ROIC) of 42%. Its balance sheet remains solid, with a current ratio of 1.5x and a debt-to-equity ratio of 1.4x.